Vaso Corporation (VASO) reported fourth-quarter revenues of $27.02 million for the period ending December 31, 2025, a decrease from $27.04 million year-over-year. The company’s net income fell 47.4% to $1.1 million, primarily due to increased selling, general, and administrative expenses, alongside a goodwill impairment charge. This performance comes as Vaso’s shares declined 0.1% following the earnings release, contrasting with a 3.9% gain in the S&P 500 during the same timeframe.
For the full year, Vaso’s revenue increased 2.7% to $89.1 million, while net income rose 64.9% to $1.6 million. Despite a 7.9% drop in IT segment revenue to $10.2 million, the professional sales service segment saw growth of 6.3%, reflecting heightened demand for GE HealthCare equipment. Operating cash flow stood at $9.3 million, a significant rise from $3.3 million in 2024, contributing to a liquidity position of $35.1 million in cash and equivalents by year-end.
The company’s gross profit improved by 5% to $54.7 million, aided by better margins, but was offset by escalating SG&A expenses, which increased 6.6% to $52.2 million. Vaso’s management cited successful order bookings and a shift in focus to higher-margin business areas following the divestiture of its healthcare IT unit as key factors in driving overall growth.
